-
Something wrong with this record ?
Methylene Blue in the Treatment of Neuropsychiatric Disorders
M. Alda,
Language English Country New Zealand
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
NLK
ProQuest Central
from 2008-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2008-01-01 to 1 year ago
Psychology Database (ProQuest)
from 2008-01-01 to 1 year ago
- MeSH
- Antidepressive Agents therapeutic use MeSH
- Bipolar Disorder drug therapy MeSH
- Humans MeSH
- Methylene Blue therapeutic use MeSH
- Neuroprotective Agents therapeutic use MeSH
- Fear drug effects MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Methylene blue is a long-established drug with complex pharmacology and multiple clinical indications. Its diverse mechanisms of action are most likely responsible for the large variety of its clinical effects. Of interest to psychiatrists, methylene blue has antidepressant, anxiolytic, and neuroprotective properties documented by both animal and human studies. Its stabilizing effect on mitochondrial function and dose-dependent effect on the generation of reactive oxygen species are of significant heuristic value. For these reasons, methylene blue holds promise as a proof-of-concept treatment of organic/neurodegenerative disorders and as a neuroprotective agent in general. In psychiatry, methylene blue has been used for over a century. It was tried successfully in the treatment of psychotic and mood disorders and as a memory enhancer in fear-extinction training. Particularly promising results have been obtained in both short- and long-term treatment of bipolar disorder. In these studies, methylene blue produced an antidepressant and anxiolytic effect without risk of a switch into mania. Long-term use of methylene blue in bipolar disorder led to a better stabilization and a reduction in residual symptoms of the illness. It is usually well tolerated, but caution is needed in the light of its inhibitory effect on monoamine oxidase A.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025733
- 003
- CZ-PrNML
- 005
- 20201222160345.0
- 007
- ta
- 008
- 201125s2019 nz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s40263-019-00641-3 $2 doi
- 035 __
- $a (PubMed)31144270
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a nz
- 100 1_
- $a Alda, Martin $u Department of Psychiatry, Dalhousie University, 5909 Veterans' Memorial Lane, Halifax, NS, B3H 2E2, Canada. malda@dal.ca. National Institute of Mental Health, Klecany, Czech Republic. malda@dal.ca.
- 245 10
- $a Methylene Blue in the Treatment of Neuropsychiatric Disorders / $c M. Alda,
- 520 9_
- $a Methylene blue is a long-established drug with complex pharmacology and multiple clinical indications. Its diverse mechanisms of action are most likely responsible for the large variety of its clinical effects. Of interest to psychiatrists, methylene blue has antidepressant, anxiolytic, and neuroprotective properties documented by both animal and human studies. Its stabilizing effect on mitochondrial function and dose-dependent effect on the generation of reactive oxygen species are of significant heuristic value. For these reasons, methylene blue holds promise as a proof-of-concept treatment of organic/neurodegenerative disorders and as a neuroprotective agent in general. In psychiatry, methylene blue has been used for over a century. It was tried successfully in the treatment of psychotic and mood disorders and as a memory enhancer in fear-extinction training. Particularly promising results have been obtained in both short- and long-term treatment of bipolar disorder. In these studies, methylene blue produced an antidepressant and anxiolytic effect without risk of a switch into mania. Long-term use of methylene blue in bipolar disorder led to a better stabilization and a reduction in residual symptoms of the illness. It is usually well tolerated, but caution is needed in the light of its inhibitory effect on monoamine oxidase A.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antidepresiva $x terapeutické užití $7 D000928
- 650 _2
- $a bipolární porucha $x farmakoterapie $7 D001714
- 650 _2
- $a strach $x účinky léků $7 D005239
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a methylenová modř $x terapeutické užití $7 D008751
- 650 _2
- $a neuroprotektivní látky $x terapeutické užití $7 D018696
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 773 0_
- $w MED00001186 $t CNS drugs $x 1179-1934 $g Roč. 33, č. 8 (2019), s. 719-725
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31144270 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222160341 $b ABA008
- 999 __
- $a ok $b bmc $g 1599878 $s 1116419
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 33 $c 8 $d 719-725 $e - $i 1179-1934 $m CNS drugs $n CNS Drugs $x MED00001186
- LZP __
- $a Pubmed-20201125